Adherex Technologies (FENC)
(Delayed Data from NSDQ)
$9.75 USD
+0.33 (3.50%)
Updated May 10, 2024 04:00 PM ET
After-Market: $9.79 +0.04 (0.41%) 7:30 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FENC 9.75 +0.33(3.50%)
Will FENC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FENC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FENC
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
FENC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Other News for FENC
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
Fennec Pharmaceuticals (FENC) Gets a Buy from Capital One Financial
FENC Makes Notable Cross Below Critical Moving Average
Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)
Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook